Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$132.43 USD

132.43
322,778

+3.19 (2.47%)

Updated Oct 14, 2024 04:00 PM ET

After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.

LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down

Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.

BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test

BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.

Charles River (CRL) Launches Animal-Free Endotoxin Test

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.

Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment

Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.

Bruker (BRKR) to Advance in Lab Automation With New Buyout

This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."

AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.

BD (BDX) Collaborates With Hamilton to Benefit Researchers

Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.

Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?

Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.

Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform

Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.

Here's Why Integer (ITGR) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Reasons to Add Merit Medical (MMSI) to Your Portfolio Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Dexcom (DXCM) Set to Solidify Its Business Throughout EMEA

Dexcom (DXCM), opening a new manufacturing facility in the West of Ireland, is expected to boost production of rtCGM sensors and create employment.